Treatment Adjustment in commonly used Biologics for the treatment of moderate to severe chronic plaque psoriasis: a German real world retrospective study (TABU)
- Conditions
- Plaque PsoriasisL40Psoriasis
- Registration Number
- DRKS00017588
- Lead Sponsor
- AbbVie Deutschland GmbH & Co. KG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 983
Inclusion Criteria
Adult patients (between 18 and 65 years of age) whose primary indication for biologic therapy was moderate to severe plaque PsO having received a biologic for a minimum of 36 weeks with either Adalimumab, Guselkumab, Ixekizumab, Secukinumab or Ustekinumab.
Patients who received the induction doses of the biologic as per local label.
Exclusion Criteria
- Patients having participated in interventional clinical trial(s) during the chart review time period
- Patients receiving biologics during pregnancy
- Patients stopping biologic therapy due to upfront planned surgeries
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method • To assess the time from initiation of a biologic treatment to first treatment adjustment in the overall study population and per biologic.<br>• Time in days from treatment initiation to treatment adjustment (collected as Yes/No answer in the CRF). Since this is a retrospective one time record, no explicit time for the primary endpoint is set.
- Secondary Outcome Measures
Name Time Method • To assess the relative frequency of different treatment adjustments types in the overall study population and per biologic <br>• To assess the duration of different treatment adjustments types in the overall study population and per biologic <br>• To assess the underlying reasons for treatment adjustments in the overall study population and per biologic<br>• To assess the effectiveness of each treatment in the overall study population and per biologic <br>• To assess the patient characteristics in the group of patients with intensified therapy (dose increase, interval shortening or start of an additional therapy) <br>• To assess the influence of office administration vs. home self-administration on treatment adjustments in the overall study population and per biologic